Cardiovascular effects and mechanisms of sodium-glucose cotransporter-2 inhibitors
Sodium-glucose cotransporter-2 inhibitors (SGLT2 inhibitors) are a new type of drug for the treatment of diabetes, and they have been proven to have a good hypoglycemic effect. Several lines of clinical evidence have shown that SGLT2 inhibitors can significantly reduce the risks of atherosclerosis,...
Guardado en:
Autores principales: | Fan Yang, Ran Meng, Da-Long Zhu |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
KeAi Communications Co., Ltd.
2020
|
Materias: | |
Acceso en línea: | https://doaj.org/article/7cdbba4d6c314a6a9f286fa7af3beceb |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
Cardiovascular effects of sodium glucose cotransporter 2 inhibitors
por: Santos Cavaiola T, et al.
Publicado: (2018) -
Cardioprotective mechanisms of sodium-glucose cotransporter 2 inhibitors
por: A. M. Mkrtumyan, et al.
Publicado: (2021) -
Extraglycemic Effects of SGLT2 Inhibitors: A Review of the Evidence
por: Bonora BM, et al.
Publicado: (2020) -
The Efficacy and Safety of Sodium-Glucose Cotransporter-2 Inhibitors in Patients with Advanced-Stage Diabetic Kidney Disease Taking Renin-Angiotensin System Blockers
por: Hirai K, et al.
Publicado: (2020) -
Prolonged ketosis and glycosuria secondary to SGLT2 inhibitor therapy
por: David Bobrowski, et al.
Publicado: (2021)